An interventional study of EXTEND Plus and EXTEND in Diabetes Mellitus, Type 2 and Hypertension, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Duke University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Diabetes Mellitus, Type 2 by Duke University — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Duke University.
Among the 29 studies in Diabetes Mellitus, Type 2 by Duke University, this one is the 8th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2022, is one of 23 with no phase, and was the 22nd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 29 studies in Diabetes Mellitus, Type 2 by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 113 across the 26 interventional studies, 202 across the 3 observational. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
2 of the studies in Diabetes Mellitus, Type 2 by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06906627Duke UniversityImplementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) | 2027-04-01 |
| NCT06906640Duke UniversityImplementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Diabetes Mellitus, Type 2 by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether the self-management of diabetes and hypertension can be improved with the use of mobile monitoring devices and nursing support.
EXpanding Technology-Enabled, Nurse-Delivered Chronic Disease Care (EXTEND) seeks to address evidence gaps that prevent practical use of mobile monitoring-enabled telehealth for clinic-refractory chronic diseases, with an initial focus on Persistent Poorly Controlled Diabetes Mellitus (PPDM) and hypertension. Because our population has already proven refractory to usual care, we will conduct an active comparator randomized trial (N=220) of two 12-month interventions: 1) mobile monitoring as a self-management tool (EXTEND); and 2) a nurse-delivered intervention incorporating mobile monitoring, self-management support, and medication management (EXTEND Plus). The medication management is a care team approach where the nurse works with a Pharmacist who has prescribing rights to optimize medications for the patients. This proposal will also allow us to examine a novel application for mobile monitoring technologies, as tools for predicting patient safety events.
Aim 1: Compare the effectiveness of the two 12-month EXTEND interventions for PPDM and hypertension. Hypothesis 1a: Compared to EXTEND, EXTEND Plus will improve primary (HbA1c) and secondary outcomes (e.g., blood pressure, weight, self-management measures) at 12 months; Hypothesis 1b: The relative effects of each intervention will be sustained at 24 months; Hypothesis 1c: Subgroup analyses will identify characteristics associated with high responsiveness to each intervention.
Aim 2: Guide scaling and dissemination of the EXTEND interventions by: (A) interviewing patients and stakeholders to clarify implementation barriers, facilitators and process requirements; (B) comparing intervention costs against potential reimbursement mechanisms; and (C) understanding the role of climate change and other social drivers of health on diabetes self-management and intervention engagement.
Aim 3: Explore the value of combining mobile monitoring and EHR data for predicting patient safety events (hospitalizations, emergency visits) in the EXTEND study cohort over 24 months. Participants will monitor their data using a suite of remote monitoring devices. Data will be analyzed with PACE by our team. If participants are randomized to the telehealth arm, these data will be reviewed by a RN during a telehealth visit to aid in clinical decision making.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EXTEND participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS). Participants can review data and trends within the device apps and modify self-management practices accordingly. The EXTEND group continues chronic disease care with their existing providers during the study, and are instructed at baseline to address management questions via their primary clinics' established avenues (as would be the case for any patient using mobile monitoring in clinical practice).
Behavioral: EXTEND
EXTEND Plus participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS) for use as part of nurse-delivered intervention combining mobile monitoring, self-management support, and medication management. The intervention is administered by clinical registered nurses (RNs) from Duke Primary Care (DPC) or Duke Endocrinology. For the medication management component, RNs work with a study PharmD affiliated with the participant's clinic. The PharmD determines if medication changes are needed, and prescribes accordingly. The RNs deliver EXTEND Plus via scheduled telephone encounters throughout the 12-month intervention. The initial encounter frequency is every two weeks, but may be extended to every four weeks for patients achieving treatment goals.
Behavioral: EXTEND Plus
The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.
EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.
Change in HbA1c
Change in blood sugar (glucose) attached to hemoglobin. Validated point-of-care or lab-based test.
Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months
Change in Systolic Blood Pressure
Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.
Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months
Change in Diastolic Blood Pressure
Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.
Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months
Change in Weight
Measurement taken with lab scale, when patient is lightly clothed, shoes off.
Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months
Change is Diabetes Distress Scale
Measure of diabetes distress and burden using the Diabetes Distress Scale (DDS): 17 items, Scale 1-6. Scoring: Average. Higher score indicates higher distress level.
Time frame: Baseline, 6, 12, 18 and 24 months
Change in Diabetes Self-Management Questionnaire
Measure of diabetes self-care. Diabetes Self-Management Questionnaire (DSMQ): 16 items, Scale 0-3. Scoring: Sum and transform to fall between 0-10. Higher score indicates more effective self-care.
Time frame: Baseline, 6, 12, 18 and 24 months
Change in Perceived Competence Scale
Measure of diabetes self-efficacy and capacity. Perceived Competence Scale (PCS): 4 items, Scale 1-7. Scoring: average (1-7) Higher score indicates greater self-efficacy.
Time frame: Baseline, 6, 12, 18 and 24 months
Change in Medication Non-adherence
Validated self-report measure using Voils' medication non-adherence measure. Voils 1. Full name: Voils Medication Nonadherence Measure 2. Construct: assesses how often a patient misses their prescribed medication and why 3. Scale range: 1-5 (the scale consists of 6 likert scale items ranging from 1=None of the time to 5=Every time. The total score is obtained by taking the mean of the items) 4. Higher scores indicate greater medication non-adherence. 5. There are no subscales.
Time frame: Baseline, 6, 12, 18 and 24 months
Change in Diabetes Knowledge
Diabetes Knowledge Questionnaire (DKQ) is a 24-item validated measure. Diabetes Knowledge 1. Full name: Diabetes Knowledge Questionnaire 2. Construct: assesses diabetes knowledge 3. Scale range: 0-24 (the scale consists of 24 yes-no items that assess diabetes knowledge. One point is given for each item answered correctly.) 4. Greater scores indicate greater knowledge of diabetes 5. There are no subscales.
Time frame: Baseline, 6, 12, 18 and 24 months
| Milestone | EXTEND Plus | EXTEND |
|---|---|---|
| Started | 110 | 110 |
| Completed | 91 | 90 |
| Not completed | 19 | 20 |
| Withdrew: Withdrawn | 4 | 5 |
| Withdrew: Lost to follow-up | 15 | 15 |
Change in blood sugar (glucose) attached to hemoglobin. Validated point-of-care or lab-based test.
| percent change from baseline | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 3 months | -0.8 ± 2.0 | -0.9 ± 1.7 |
| Baseline to 6 months | -1.0 ± 1.9 | -0.8 ± 2.3 |
| Baseline to 9 months | -1.3 ± 2.3 | -0.8 ± 2.5 |
| Baseline to 12 months | -1.1 ± 2.3 | -0.9 ± 2.3 |
| Baseline to 18 months | -1.1 ± 2.4 | -0.8 ± 2.6 |
| Baseline to 24 months | -1.1 ± 2.3 | -1.2 ± 2.5 |
Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.
| mmHg | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 3 months | -0.6 ± 20.6 | -2.4 ± 14.0 |
| Baseline to 6 months | -0.5 ± 21.5 | 1.0 ± 16.0 |
| Baseline to 9 months | -3.4 ± 20.0 | 2.0 ± 20.3 |
| Baseline to 12 months | -3.0 ± 20.8 | 2.1 ± 18.3 |
| Baseline to 18 months | -0.7 ± 20.9 | 0.9 ± 19.7 |
| Baseline to 24 months | -5.2 ± 25.5 | 1.8 ± 18.0 |
Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.
| mmHg | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 3 months | -0.2 ± 10.1 | -0.4 ± 7.8 |
| Baseline to 6 months | -0.4 ± 10.7 | 1.0 ± 8.7 |
| Baseline to 9 months | -1.6 ± 10.2 | 0.9 ± 10.4 |
| Baseline to 12 months | -0.4 ± 10.9 | 1.6 ± 9.2 |
| Baseline to 18 months | 0.9 ± 10.3 | 1.7 ± 9.8 |
| Baseline to 24 months | -1.7 ± 12.3 | 1.5 ± 10.7 |
Measurement taken with lab scale, when patient is lightly clothed, shoes off.
| lbs | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 3 months | -2.3 ± 11.4 | -1.2 ± 20.2 |
| Baseline to 6 months | -4.6 ± 14.1 | -0.7 ± 15.5 |
| Baseline to 9 months | -7.5 ± 19.2 | -1.6 ± 17.5 |
| Baseline to 12 months | -8.2 ± 18.7 | -3.4 ± 18.1 |
| Baseline to 18 months | -9.9 ± 18.4 | -5.7 ± 21.7 |
| Baseline to 24 months | -9.0 ± 21.1 | -7.9 ± 22.4 |
Measure of diabetes distress and burden using the Diabetes Distress Scale (DDS): 17 items, Scale 1-6. Scoring: Average. Higher score indicates higher distress level.
| score on a scale | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 6 months | -0.4 ± 0.8 | -0.4 ± 0.9 |
| Baseline to 12 months | -0.5 ± 0.9 | -0.4 ± 0.9 |
| Baseline to 18 months | -0.6 ± 1.0 | -0.4 ± 1.0 |
| Baseline to 24 months | -0.5 ± 1.0 | -0.5 ± 0.9 |
Measure of diabetes self-care. Diabetes Self-Management Questionnaire (DSMQ): 16 items, Scale 0-3. Scoring: Sum and transform to fall between 0-10. Higher score indicates more effective self-care.
| score on a scale | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 6 months | 0.7 ± 1.5 | 0.5 ± 1.5 |
| Baseline to 12 months | 0.9 ± 1.5 | 0.5 ± 1.4 |
| Baseline to 18 months | 0.8 ± 1.5 | 0.6 ± 1.6 |
| Baseline to 24 months | 0.8 ± 1.5 | 0.8 ± 1.6 |
Measure of diabetes self-efficacy and capacity. Perceived Competence Scale (PCS): 4 items, Scale 1-7. Scoring: average (1-7) Higher score indicates greater self-efficacy.
| score on a scale | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 6 months | 0.4 ± 1.6 | 0.4 ± 1.6 |
| Baseline to 12 months | 0.5 ± 1.7 | 0.3 ± 1.6 |
| Baseline to 18 months | 0.5 ± 1.9 | 0.5 ± 1.7 |
| Baseline to 24 months | 0.7 ± 1.6 | 0.7 ± 1.7 |
Validated self-report measure using Voils' medication non-adherence measure. Voils 1. Full name: Voils Medication Nonadherence Measure 2. Construct: assesses how often a patient misses their prescribed medication and why 3. Scale range: 1-5 (the scale consists of 6 likert scale items ranging from 1=None of the time to 5=Every time. The total score is obtained by taking the mean of the items) 4. Higher scores indicate greater medication non-adherence. 5. There are no subscales.
| score on a scale | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 6 months | -0.3 ± 0.7 | -0.0 ± 0.6 |
| Baseline to 12 months | -0.3 ± 0.7 | -0.1 ± 0.8 |
| Baseline to 18 months | -0.2 ± 1.0 | -0.3 ± 0.7 |
| Baseline to 24 months | -0.3 ± 0.9 | -0.3 ± 0.7 |
Diabetes Knowledge Questionnaire (DKQ) is a 24-item validated measure. Diabetes Knowledge 1. Full name: Diabetes Knowledge Questionnaire 2. Construct: assesses diabetes knowledge 3. Scale range: 0-24 (the scale consists of 24 yes-no items that assess diabetes knowledge. One point is given for each item answered correctly.) 4. Greater scores indicate greater knowledge of diabetes 5. There are no subscales.
| score on a scale | EXTEND Plus | EXTEND |
|---|---|---|
| Baseline to 6 months | 0.6 ± 2.5 | 0.7 ± 2.8 |
| Baseline to 12 months | 0.9 ± 3.4 | 1.2 ± 3.2 |
| Baseline to 18 months | 1.1 ± 3.8 | 1.5 ± 2.4 |
| Baseline to 24 months | 1.4 ± 2.8 | 1.7 ± 3.0 |
Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXTEND Plus | 1/110 (0.9%) | 31/110 (28.2%) | 26/110 (23.6%) |
| EXTEND | 2/110 (1.8%) | 29/110 (26.4%) | 27/110 (24.5%) |
| Event | EXTEND Plus | EXTEND |
|---|---|---|
| Stroke/stroke evaluationNervous system disorders | 8/110 | 5/110 |
| Abdominal painGastrointestinal disorders | 3/110 | 4/110 |
| Cancer-related admissionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/110 | 0/110 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/110 | 3/110 |
| Chest painCardiac disorders | 3/110 | 3/110 |
| Diabetic foot infectionInfections and infestations | 3/110 | 1/110 |
| Heart failure/fluid overloadCardiac disorders | 3/110 | 0/110 |
| Musculoskeletal or other painMusculoskeletal and connective tissue disorders | 3/110 | 2/110 |
| PancreatitisGastrointestinal disorders | 3/110 | 2/110 |
| HypotensionVascular disorders | 2/110 | 2/110 |
| Event | EXTEND Plus | EXTEND |
|---|---|---|
| Musculoskeletal or other painMusculoskeletal and connective tissue disorders | 12/110 | 12/110 |
| Abdominal painGastrointestinal disorders | 3/110 | 4/110 |
| Respiratory infectionRespiratory, thoracic and mediastinal disorders | 3/110 | 4/110 |
| Hyperglycemia without DKAMetabolism and nutrition disorders | 1/110 | 3/110 |
| Orthopedic injuryMusculoskeletal and connective tissue disorders | 3/110 | 3/110 |
| Skin/soft tissue infectionInfections and infestations | 3/110 | 1/110 |
| Chest painCardiac disorders | 1/110 | 2/110 |
| Nausea/vomitingGastrointestinal disorders | 2/110 | 0/110 |
| PancreatitisGastrointestinal disorders | 0/110 | 2/110 |
| HypertensionVascular disorders | 0/110 | 1/110 |
| Age, Continuous(years) | EXTEND Plus | EXTEND | Total |
|---|---|---|---|
| Mean | 54.1 ± 10.1 | 54.9 ± 10.5 | 54.5 ± 10.3 |
| Sex/Gender, Customized(Participants) | EXTEND Plus | EXTEND | Total |
|---|---|---|---|
| Male | 35 | 44 | 79 |
| Female | 75 | 65 | 140 |
| Unknown | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | EXTEND Plus | EXTEND | Total |
|---|---|---|---|
| Black/African American | 77 | 73 | 150 |
| White | 19 | 28 | 47 |
| Other/Unknown | 14 | 9 | 23 |
| Region of Enrollment(participants) | EXTEND Plus | EXTEND | Total |
|---|---|---|---|
| United States | 110 | 110 | 220 |
| HbA1c(percent) | EXTEND Plus | EXTEND | Total |
|---|---|---|---|
| Mean | 9.8 ± 1.7 | 9.8 ± 1.7 | 9.8 ± 1.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Our data will be made available for use by investigators not associated with the proposed study within 3 years after the primary results have been published. We will prepare a clear and searchable documentation of the database including a data dictionary, and its linkage to the pertinent study protocols and forms so that diverse investigators can make effective use of the data. For investigators interested in prospective collaborations, we will explore other options to provide support.
Supporting information: Study protocol, Analytic code
Time frame: Within 3 years of study data publication.
Access criteria: For all prospective opportunities (e.g., access to datasets, collaborative studies), we will widely advertise them on Duke Websites and at appropriate scientific meetings.
Ran from Apr 2022 to primary completion in Aug 2025, 39 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 39 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.